Istiratumab
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers[1][2][3].
Product Specifications
CAS Number
[1509928-04-4]
Product Name Alternative
MM 141; MM-005
UNSPSC
12352203
Target
EGFR; IGF-1R
Type
Inhibitory Antibodies
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/istiratumab.html
Purity
98.45
Solubility
10 mM in DMSO
Smiles
[Istiratumab]
Molecular Weight
(199.63 kDa)
References & Citations
[1]Kundranda M, et al. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE) . Ann Oncol. 2020 Jan;31 (1) :79-87. |[2]Camblin AJ, et al. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Clin Cancer Res. 2018 Jun 15;24 (12) :2873-2885. |[3]Camblin AJ, et al. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer. Sci Rep. 2019 Nov 14;9 (1) :16832.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
PCP55-30072U-01 25 µg
PerCP-Cy5.5 Anti-Mouse/Human CD11b Antibody (M1/70)
Sign In for Pricing
View Details 
PCP55-30072U-02 100 µg
PerCP-Cy5.5 Anti-Mouse/Human CD11b Antibody (M1/70)
Sign In for Pricing
View Details 